

**GOVERNMENT OF INDIA
MINISTRY OF SCIENCE & TECHNOLOGY
DEPARTMENT OF BIOTECHNOLOGY**

**RAJYA SABHA
UNSTARRED QUESTION NO. 1090
TO BE ANSWERED ON 15/12/2022
Mission COVID Suraksha**

1090 Dr. K. Laxman:

Will the Minister of *Science and Technology* be pleased to state:

- (a) whether 'Mission COVID Suraksha' program, a centrally sponsored program launched in November 2020 has established three Animal Challenge Studies and three laboratories for performing Clinical Immunogenicity Assays till now, if so, the details thereof;
- (b) whether the sanctioned amount for phase II has increased compared to phase I where the sanctioned amount was ₹ 900 crores for a period of 12 months and if so, the details thereof; and
- (c) the details of number of vaccines as per the Department of Biotechnology report?

ANSWER

MINISTER OF STATE (INDEPENDENT CHARGE) OF SCIENCE AND TECHNOLOGY AND EARTH SCIENCES

(DR. JITENDRA SINGH)

(a) Yes, Sir.

Under 'Mission COVID Suraksha', 5 laboratories for Animal Challenge Studies and 6 Clinical Immunogenicity Assay laboratories have been supported. Details of the same are as follows:

S. No.	Facilities for Animal Challenge Studies – Laboratory/Institute
1.	Institute of Life Sciences (ILS), Bhubaneshwar
2.	Indian Institute of Science (IISc.), Bengaluru
3.	National Centre for Biological Sciences (NCBS), Bengaluru
4.	Translational Health Science and Technology Institute (THSTI), NCR Biotech Science Cluster, Faridabad
5.	Institute for Stem Cell Biology and Regenerative Medicine (inStem), Bengaluru

S. No.	Facilities for Clinical Immunogenicity Assays – Laboratory/Institute
1.	Interactive Research School for Health Affairs (IRSHA), Pune
2.	Syngene International Limited, Bengaluru
3.	Translational Health Science and Technology Institute (THSTI), NCR Biotech Science Cluster, Faridabad
4.	Institute of Life Sciences (ILS), Bhubaneswar
5.	Mazumdar Shaw Medical Foundation, Bengaluru
6.	Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru

(b) ‘Mission COVID Suraksha’ has been sanctioned for implementation at a cost of Rs. 900 crores. The sanctioned cost has not increased as there is no Phase II of the Mission.

(c) Details of five vaccines supported and developed under ‘Mission COVID Suraksha’ are as follows:

S. No.	Vaccines	Grantee/Vaccine Developer	Current Status
1.	ZyCoV-D (DNA)	Zydus Lifesciences Ltd.	Received EUA
2.	Corbevax TM (Recombinant protein subunit)	Biological E Ltd.	Received EUA
3.	GEMCOVAC-19 (mRNA)	Gennova Biopharmaceuticals Ltd.	Received EUA
4.	iNCOVACC (Adenovirus vectored vaccine)	Bharat Biotech International Ltd.	Received EUA
5.	Virus Like Particle vaccine	Genique Life Sciences Ltd.	Advanced pre-clinical; foreclosed
